Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog
- PMID: 6117570
- PMCID: PMC370908
- DOI: 10.1172/jci110359
Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog
Abstract
The hepatic and renal metabolism of somatostatin-like immunoreactivity (SLI) was assessed simultaneously in an in vivo dog model. The hepatic extraction of this peptide was 29.4 +/- 2.3% and was similar for endogenous and infused exogenous SLI. The renal extraction was 62.3 +/- 5%. The renal clearance of SLI was significantly greater than that of inulin indicating that the peptide is handled by peritubular uptake from postglomerular blood in addition to glomerular filtration. In both organs SLI extraction was not saturable even at arterial concentrations in excess of 100 times physiological range. The overall metabolic clearance rate of SLI was 19.7 +/- 1.6 ml/kg per minute of which 32.7 +/- 4.6% was contributed by hepatic and 37 +/- 4.9% by renal uptake mechanisms. The plasma half disappearance time of exogenously infused SLI was 1.9 +/- 0.3 min. The studies indicate that in the dog, the liver and kidney are both major sites of SLI metabolism, together accounting for 70.0 +/- 8.7% of the metabolic clearance of the peptide.
Similar articles
-
Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog.Am J Physiol. 1983 Aug;245(2):E171-7. doi: 10.1152/ajpendo.1983.245.2.E171. Am J Physiol. 1983. PMID: 6881330
-
Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism.Acta Endocrinol (Copenh). 1983 Mar;102(3):420-7. doi: 10.1530/acta.0.1020420. Acta Endocrinol (Copenh). 1983. PMID: 6338678
-
The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action.Endocrinology. 1982 Nov;111(5):1698-703. doi: 10.1210/endo-111-5-1698. Endocrinology. 1982. PMID: 6127205
-
Somatostatin-like immunoreactivity in rat blood. Characterization, regional differences, and responses to oral and intravenous glucose.J Clin Invest. 1978 May;61(5):1410-4. doi: 10.1172/JCI109059. J Clin Invest. 1978. PMID: 659602 Free PMC article.
-
Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs.Gut. 1981 Sep;22(9):732-7. doi: 10.1136/gut.22.9.732. Gut. 1981. PMID: 6117506 Free PMC article.
Cited by
-
Biochemistry and physiology of gastrointestinal somatostatin.Dig Dis Sci. 1989 Mar;34(3 Suppl):5S-13S. doi: 10.1007/BF01536041. Dig Dis Sci. 1989. PMID: 2563966 Review.
-
C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog.J Clin Invest. 1984 Nov;74(5):1821-9. doi: 10.1172/JCI111601. J Clin Invest. 1984. PMID: 6389599 Free PMC article.
-
Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction.J Clin Invest. 1983 Sep;72(3):1114-23. doi: 10.1172/JCI111036. J Clin Invest. 1983. PMID: 6350363 Free PMC article.
-
Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.Clin Pharmacokinet. 2006;45(10):1003-11. doi: 10.2165/00003088-200645100-00004. Clin Pharmacokinet. 2006. PMID: 16984213 Clinical Trial.
-
Endogenous somatostatin and the gut.Gut. 1986 Apr;27(4):457-67. doi: 10.1136/gut.27.4.457. Gut. 1986. PMID: 2870009 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources